Skip to main content
Home
  • Dansk
  • English

Servicemenu

  • News
  • Events
    • Previous Events
  • Themes
  • Contact
    • Contact Grants & Prizes
    • Press Contact
    • Contact The Lundbeck Foundation
    • Departments
    • Logo and Design

Hovedmenu

  • Business Activities
    • Lundbeckfonden BioCapital
      • About Lundbeckfonden BioCapital
      • Lundbeckfonden BioCapital News
      • Lundbeckfonden BioCapital Portfolio
      • Lundbeckfonden BioCapital Portfolio News
    • Strategic Investments
      • Long-Term Value Creation
      • Strategic Ownership
    • Invest
  • Grants & Prizes
    • For applicants
      • Apply for grants
      • Processing of applications
      • Review Panels
    • For grant recipients
      • Terms and Conditions - Research Grants
      • Reporting
      • Distribution of funds
    • What we have funded
      • Fellowships
      • Professorships
      • Ascending Investigators
      • Pre-Graduate Scholarships
      • LF Postdocs
      • Visiting Professorships
      • LF Experiment
      • Talentpriser
      • The Brain Prize
      • Young Investigator Prize
      • Alle
    • News - Grants & Prizes
    • Research Stories
  • Neurotorium
  • The Brain Prize
    • Overview
    • Nominations & Selection Process
    • Press and Logo
    • News
  • About Us
    • The Organisation
      • Board of Directors and Management
      • Vacancies
    • Who are we?
    • History and Statutes
    • Strategy and Purpose
      • Bringing Discoveries to Lives
    • Social Responsibility and Transparency
      • Recommendations on Foundation Governance, Corporate Governance and Transparency
      • Governance
      • Active voice in public debate
      • Policies
      • Whistleblower
    • Publikationer
      • Annual Reports
      • Sustainability Reports
      • The Magazine
      • Anniversary Book
  • Apply and Nominate

Hovedmenu - mobil

  • Business Activities
    • Lundbeckfonden BioCapital
      • About Lundbeckfonden BioCapital
      • Lundbeckfonden BioCapital News
      • Lundbeckfonden BioCapital Portfolio
      • Lundbeckfonden BioCapital Portfolio News
    • Strategic Investments
      • Long-Term Value Creation
      • Strategic Ownership
    • Invest
  • Grants & Prizes
    • For applicants
      • Apply for grants
      • Processing of applications
      • Review Panels
    • For grant recipients
      • Terms and Conditions - Research Grants
      • Reporting
      • Distribution of funds
    • What we have funded
      • Fellowships
      • Professorships
      • Ascending Investigators
      • Pre-Graduate Scholarships
      • LF Postdocs
      • Visiting Professorships
      • LF Experiment
      • Talentpriser
      • The Brain Prize
      • Young Investigator Prize
      • Alle
    • News - Grants & Prizes
    • Research Stories
  • Neurotorium
  • The Brain Prize
    • Overview
    • Nominations & Selection Process
    • Press and Logo
    • News
  • About Us
    • The Organisation
      • Board of Directors and Management
      • Vacancies
        • Personal Data Policy for Recruitment
    • Who are we?
    • History and Statutes
    • Strategy and Purpose
      • Bringing Discoveries to Lives
    • Social Responsibility and Transparency
      • Recommendations on Foundation Governance, Corporate Governance and Transparency
      • Governance
      • Active voice in public debate
      • Policies
      • Whistleblower
    • Publikationer
      • Annual Reports
      • Sustainability Reports
      • The Magazine
      • Anniversary Book
  • Apply and Nominate

Servicemenu - mobil

  • News
  • Events
    • Previous Events
  • Themes
  • Analyser
  • Contact
    • Contact Grants & Prizes
    • Press Contact
    • Contact The Lundbeck Foundation
    • Departments
    • Logo and Design
  • Dansk
  • English

Breadcrumb

  1. Home
  2. Business Activities
  3. Lundbeckfonden BioCapital
  4. Trevi Therapeutics

Trevi Therapeutics

Trevi Therapeutics develops Nalbuphine® ER for chronic pruritus (itch).

The Company has generated clinical proof of concept data in two important itch conditions: uremic pruritus and prurigo nodularis.and is starting phase IIb clinical studies

Related news about Trevi Therapeutics

  • Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio™ in the Treatment of Prurigo Nodularis
  • Trevi Therapeutics Announces $55 Million Private Placement Priced At-the-Market
  • Trevi Therapeutics Initiates Pivotal Clinical Trial of Nalbuphine ER for the Treatment of Pruritus in Prurigo Nodularis
  • Trevi Therapeutics Appoints Yann Mazabraud as Chief Commercial Officer and Head of International
  • Trevi Therapeutics to Present at Needham & Company’s 17th Annual Healthcare Conference
Trevi Therapeutics Logo
Trevi Therapeutics' website

Lundbeckfonden BioCapital

Invested
2017

IPO in 2019 – TRVL (Nasdaq)

Location

New Haven, Connecticut, USA

Footer logo
The Lundbeck Foundation annually distributes more than DKK 500 mio. to Danish-based healthcare science research, primarily with a focus on the brain.

Lundbeckfonden
Scherfigsvej 7
2100 København Ø

CVR
11814913

Links

  • Cookie-Policy
  • Disclaimer & Privacy
  • History and Statutes
  • Our Strategy
  • Events
  • Contact
  • Jobs
Follow us
Facebook
Twitter
LinkedIn
Youtube